Article Sidebar
Published:
Apr 28, 2022Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Mitigating effect of clopidogrel and systematic management on adverse events after interventional therapy for coronary heart disease
Abstract
Purpose: To investigate the efficacy of clopidogrel combined with systemic management care in the prevention of adverse events in patients with coronary heart disease after interventional therapy.
Methods: 100 patients undergoing interventional therapy after coronary heart disease admitted to Jinan Third People’s Hospital from April 2018 to April 2020 were assigned at a ratio of 1:1 either into control (low-molecular-weight heparin (LMWH) injection) or study groups randomly (clopidogrel plus system management care). Thrombin time, prothrombin time, fibrinogen, incidence of adverse events, NIHSS score and QLI score were determined for the two groups.
Results: There thrombin time, prothrombin time and fibrinogen in the two groups were similar (p >0.05). The study group showed a significantly lower incidence of adverse events than the control group (p < 0.05). The treatment administered to the study group resulted in a higher QLI (quality of life) scores than those in the control group (p < 0.05). Remarkably lower National Institutes of Health Stroke Scale (NIHSS) score was reported in the study group versus control group (p < 0.05).
Conclusion: Clopidogrel plus systemic management care might be a preferable therapeutic strategy for patients with coronary heart disease undergoing interventional therapy. It reduces the incidence of adverse events, significantly improves the quality of life of patients, and enhances neurological function. Thus, this therapeutic strategy has significant promise in the management of coronary heart disease.
